

CORRECTION

Open Access

Correction to: Advanced imaging in adult diffusely infiltrating low-grade gliomas



Nail Bulakbaşı^{1*} and Yahya Paksoy²

Correction to: Insights Imaging

<https://doi.org/10.1186/s13244-019-0793-8>

The original article "Advanced imaging in adult diffusely infiltrating low-grade gliomas" contains errors in Table 1 in rows k_{trans} and V_e ; the correct version of Table 1 can be viewed in this Correction article.

The original article can be found online at <https://doi.org/10.1186/s13244-019-0793-8>.

* Correspondence: nail.bulakbasi@kyrenia.edu.tr

¹Medical Faculty, University of Kyrenia, Sehit Yahya Bakir Street, Karakum, Mersin-10, Kyrenia, Turkish Republic of Northern Cyprus, Turkey
Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Table 1 Radiomic data for differential diagnosis of low-grade vs high-grade gliomas

Parameters	Low-grade glioma	High-grade glioma	Cut of value ^{Ref} (Range) ^{Ref}
rCBV _{max}	Low	High	1.76 [10, 19] (0.94–3.34) [9–11, 19–21]
rCBV _{MD}	Low	High	1.44 [22] (1.08–1.81) [22]
nADC _{min}	High	Low	1.07 × 10 ⁻³ mm ² /s [24] (0.31–1.31) [23–28]
Cho/Cr ratio	Low	High	1.56 [19] (1.3–2.04) [29–31]
MK _{MD}	Low	High	0.17 [28] (0.11–0.28) [28]
FA _{TC}	Low	High	0.3 [25] (0.14–0.63) [25]
MD _{min}	High	Low	0.98 mm ² /s [25] (0.76–0.91) [25]
k _{trans}	Low	High	1.18 [22] (0.91–1.45) [22]
V _e	Low	High	1.43 [22] (1.06–1.80) [22]
ITTS grade	1.2	2.6	NA [9]
APT signal (%)	Low	High	2.23% [15] (1.53%–3.70%) [15]

rCBV_{max} maximum relative cerebral blood volume, rCBV_{MD} standardized mean difference of rCBV_{max}, nADC_{min} Normalized minimum apparent diffusion coefficient, Cho/Cr Choline/Creatine, MK_{MD} mean difference in mean kurtosis, FA_{TC} Odds ratio of fractional anisotropy in the tumor core, MD_{min} Minimum mean diffusivity, k_{trans} standardized mean difference of volume transfer coefficient, V_e standardized mean difference of volume fraction of extravascular extracellular space, ITTS Intratumoral susceptibility score, APT Percent amide proton transfer signal

Author details

¹Medical Faculty, University of Kyrenia, Sehit Yahya Bakir Street, Karakum, Mersin-10, Kyrenia, Turkish Republic of Northern Cyprus, Turkey. ²Selcuk University, Konya, Turkey.

Published online: 22 April 2020

Reference

- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2016) WHO classification of tumours of the central nervous system, revised 4th edition. IARC, Lyon.
- Sahm F, Reuss D, Koelsche C et al (2014) Farewell to oligoastrocytoma: insitu molecular genetics favor classification as either oligodendroglioma or astrocytoma. *Acta Neuropathol* 128(4):551–559. <https://doi.org/10.1007/s00401-014-1326-7>
- Bready D, Placantonakis DG (2019) Molecular pathogenesis of low-grade glioma. *Neurosurg Clin N Am* 30(1):17–25. <https://doi.org/10.1016/j.nec.2018.08.011>
- Duffau H (2016) Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up. *Acta Neurochir (Wien)* 158(1):51–58. <https://doi.org/10.1007/s00701-015-2621-3>
- National Comprehensive Cancer Network. Central nervous system cancers (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed Mar 5 2019
- Olson JJ, Kalkanis SN, Ryken TC (2015) Evidence-based clinical practice parameter guidelines for the treatment of adults with diffuse low-grade glioma: introduction and methods. *J Neurooncol* 125(3):449–456. <https://doi.org/10.1007/s11060-015-1847-5>
- Fouke SJ, Benzinger T, Gibson D, Ryken TC, Kalkanis SN, Olson JJ (2015) Therole of imaging in the management of adults with diffuse low-grade glioma: a systematic review and evidence-based clinical practice guideline. *J Neurooncol* 125(3):457–479. <https://doi.org/10.1007/s11060-015-1908-9>
- Caulo M, Panara V, Tortora D et al (2014) Data-driven grading of brain gliomas: a multiparametric MR imaging study. *Radiology* 272(2):494–503. <https://doi.org/10.1148/radiol.14132040>
- Li X, Zhu Y, Kang H et al. (2015) Glioma grading by microvascular permeability parameters derived from dynamic contrast-enhanced MRI and intratumoral susceptibility signal on susceptibility weighted imaging. *Cancer Imaging* 15:4. <https://doi.org/10.1186/s40644-015-0039-z>
- Delgado AF, Delgado AF (2017) Discrimination between glioma grades I and III using dynamic susceptibility perfusion MRI: a meta-analysis. *AJNR Am J Neuroradiol* 38(7):1348–1355. <https://doi.org/10.3174/ajnr.A5218>
- Kong L, Chen H, Yang Y, Chen L (2017) A meta-analysis of arterial spin labelling perfusion values for the prediction of glioma grade. *Clin Radiol* 72(3):255–261. <https://doi.org/10.1016/j.crad.2016.10.016>
- ACR Committee on Drugs and Contrast Media (2018) ACR manual on contrast media (Version 10.3, 2018). https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Accessed 2018.
- Choi C, Ganji SK, DeBerardinis RJ et al. (2012) 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. *Nat Med* 18(4):624–629. <https://doi.org/10.1038/nm.2682>
- Tietze A, Choi C, Mickey B et al. (2018) Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. *J Neurosurg* 128(2):391–398. <https://doi.org/10.3171/2016.10.JNS161793>
- Suh CH, Park JE, Jung SC, Choi CG, Kim SJ, Kim HS (2019) Amide proton transfer-weighted MRI in distinguishing high- and low-grade gliomas: a systematic review and meta-analysis. *Neuroradiology* 61(5):525–534. <https://doi.org/10.1007/s00234-018-02152-2>
- Park JE, Kim HS, Park KJ, Choi CG, Kim SJ (2015) Histogram analysis of amide proton transfer imaging to identify contrast-enhancing low-grade brain tumor that mimics high-grade tumor: increased accuracy of MR perfusion. *Radiology* 277(1):151–161. <https://doi.org/10.1148/radiol.2015142347>
- Billar A, Badde S, Nagel A et al. (2016) Improved brain tumor classification by sodium MR imaging: prediction of IDH mutation status and tumor progression. *AJNR Am J Neuroradiol* 37(1):66–73. <https://doi.org/10.3174/ajnr.A4493>
- Pepin KM, McGee KP, Arani A et al. (2018) MR elastography analysis of glioma stiffness and IDH1-mutation status. *AJNR Am J Neuroradiol* 39(1):31–36. <https://doi.org/10.3174/ajnr.A5415>
- Law M, Yang S, Wang H et al. (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. *AJNR Am J Neuroradiol* 24(10):1989–1998
- Bulakbasi N, Kocaoglu M, Farzaliyev A, Tayfun C, Ucoz T, Somuncu I (2005) Assessment of diagnostic accuracy of perfusion MR imaging in primary and metastatic solitary malignant brain tumors. *AJNR Am J Neuroradiol* 26(9):2187–2199
- Anzalone N, Castellano A, Cadioli M et al. (2018) Brain gliomas: multicenter standardized assessment of dynamic contrast-enhanced and dynamic susceptibility contrast MR images. *Radiology* 287(3):933–943. <https://doi.org/10.1148/radiol.2017170362>
- Liang J, Liu D, Gao P et al. (2018) Diagnostic values of DCE-MRI and DSC-MRI for differentiation between high-grade and low-grade gliomas: a comprehensive meta-analysis. *Acad Radiol* 25(3):338–348. <https://doi.org/10.1016/j.acra.2017.10.001>
- Bulakbasi N, Guvenc I, Onguru O, Erdogan E, Tayfun C, Ucoz T (2004) The added value of the apparent diffusion coefficient calculation to magnetic resonance imaging in the differentiation and grading of malignant brain tumors. *J Comput Assist Tomogr* 28(6):735–746
- Server A, Kulle B, Gadmar ØB, Josefsen R, Kumar T, Nakstad PH (2011) Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas. *Eur J Radiol* 80(2):462–70. <https://doi.org/10.1016/j.ejrad.2010.07.017>

25. Miloshev VZ, Chow DS, Filippi CG (2015) Meta-analysis of diffusion metrics for the prediction of tumor grade in gliomas. *AJNR Am J Neuroradiol* 36(2):302–8. <https://doi.org/10.3174/ajnr.A4097>
26. Zhang L, Min Z, Tang M, Chen S, Lei X, Zhang X (2017) The utility of diffusion MRI with quantitative ADC measurements for differentiating high-grade from low-grade cerebral gliomas: evidence from a meta-analysis. *JNeuro Sci* 373:9–15. <https://doi.org/10.1016/j.jns.2016.12.008> Erratum in: *JNeuro Sci*. 2017;375:103–6
27. Liang R, Wang X, Li M et al. (2014) Potential role of fractional anisotropy derived from diffusion tensor imaging in differentiating high-grade gliomas from low-grade gliomas: a meta-analysis. *Int J Clin Exp Med* 7(10):3647–53
28. Falk Delgado A, Nilsson M, van Westen D, Falk Delgado A (2018) Glioma grade discrimination with MR diffusion kurtosis imaging: a meta-analysis of diagnostic accuracy. *Radiology* 287(1):119–27. <https://doi.org/10.1148/radiol.2017171315>
29. Castillo M, Smith JK, Kwock L (2000) Correlation of myo-inositol levels and grading of cerebral astrocytomas. *AJNR Am J Neuroradiol* 21(9):1645–49.
30. Wang Q, Zhang H, Zhang J et al. (2016) The diagnostic performance of magnetic resonance spectroscopy in differentiating high- from low-grade gliomas: a systematic review and meta-analysis. *Eur Radiol* 26(8):2670–84. <https://doi.org/10.1007/s00330-015-4046-z>
31. Usinskiene J, Ulyte A, Bjørnerud A et al. (2016) Optimal differentiation of high- and low-grade glioma and metastasis: a meta-analysis of perfusion, diffusion, and spectroscopy metrics. *Neuroradiology* 58(4):339–50. <https://doi.org/10.1007/s00234-016-1642-9>
32. Hilario A, Sepulveda JM, Perez-Núñez A et al. (2014) A prognostic model based on preoperative MRI predicts overall survival in patients with diffuse gliomas. *AJNR Am J Neuroradiol* 35(6):1096–1102. <https://doi.org/10.3174/ajnr.A3837>
33. Cuccarini V, Erbetta A, Farinotti M et al. (2016) Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. *J Neurooncol* 126(2):279–88
34. Villanueva-Meyer JE, Wood MD, Choi BS et al. (2018) MRI features and IDH mutational status of grade II diffuse gliomas: impact on diagnosis and prognosis. *AJR Am J Roentgenol* 210(3):621–28. <https://doi.org/10.2214/AJR.17.18457>
35. Law M, Oh S, Babb JS et al. (2006) Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging—prediction of patient clinical response. *Radiology*. 238(2):658–67
36. Nguyen TB, Cron GO, Mercier JF et al. (2015) Preoperative prognostic value of dynamic contrast-enhanced MRI-derived contrast transfer coefficient and plasma volume in patients with cerebral gliomas. *AJNR Am J Neuroradiol* 36(1):63–69. <https://doi.org/10.3174/ajnr.A4006>
37. Hlailhel C, Guilloton L, Guyotat J, Streichenberger N, Honnorat J, Cotton F (2010) Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas. *J Neurooncol* 97(1):73–80. <https://doi.org/10.1007/s11060-009-9991-4>
38. Law M, Young RJ, Babb JS et al. (2008) Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. *Radiology* 247(2):490–98. <https://doi.org/10.1148/radiol.2472070898>
39. Danchaiwittit N, Waldman AD, Tozer DJ et al. (2008) Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? *Radiology* 247(1):170–78. <https://doi.org/10.1148/radiol.2471062089>
40. Back M, Jayamanne DT, Brazier D et al. (2019) Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management. *J Med Imaging Radiat Oncol* 63(2):272–80. <https://doi.org/10.1111/1754-9485.12850>
41. Shirahata M, Ono T, Stichel D et al. (2018) Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. *Acta Neuropathol* 136(1):153–66. <https://doi.org/10.1007/s00401-018-1849-4>
42. Patel SH, Poisson LM, Brat DJ et al. (2017) T2-FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCA project. *Clin Cancer Res* 23(20):6078–85. <https://doi.org/10.1158/1078-0432.CCR-17-0560>
43. Ren Y, Zhang X, Rui W et al. (2019) Noninvasive prediction of IDH1 mutation and ATRX expression loss in low-grade gliomas using multiparametric MR radiomic features. *J Magn Reson Imaging* 49(3):808–17. <https://doi.org/10.1002/jmri.26240>
44. Hasselblatt M, Jaber M, Reuss D et al. (2018) Diffuse astrocytoma, IDH-wildtype: a dissolving diagnosis. *J Neuropathol Exp Neurol* 77(6):422–25. <https://doi.org/10.1093/jnen/nly012>
45. Brat DJ, Aldape K, Colman H, et al. (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for "diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV. *Acta Neuropathol* 136(5):805–10. <https://doi.org/10.1007/s00401-018-1913-0>
46. Wu CC, Jain R, Radmanesh A et al. (2018) Predicting genotype and survival in glioma using standard clinical MR imaging apparent diffusion coefficient images: a pilot study from the cancer genome atlas. *AJNR Am J Neuroradiol* 39(10):1814–20. <https://doi.org/10.3174/ajnr.A5794>
47. Smits M, van den Bent MJ (2017) Imaging correlates of adult glioma genotypes. *Radiology* 284(2):316–31. <https://doi.org/10.1148/radiol.2017151930>
48. Kickingeder P, Sahn F, Radbruch A et al. (2015) IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. *Sci Rep* 5:16238. <https://doi.org/10.1038/srep16238>
49. Leu K, Ott GA, Lai A et al. (2017) Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II–III diffuse gliomas. *J Neurooncol* 134(1):177–88. <https://doi.org/10.1007/s11060-017-2506-9>
50. Stadlbauer A, Zimmermann M, Kitzwögerer M et al. (2017) MR imaging-derived oxygen metabolism and neovascularization characterization for grading and IDH gene mutation detection of gliomas. *Radiology* 283(3):799–809. <https://doi.org/10.1148/radiol.2016161422>
51. Bian W, Khayal IS, Lupo JM et al. (2009) Multiparametric characterization of grade 2 glioma subtypes using magnetic resonance spectroscopic, perfusion, and diffusion imaging. *Transl Oncol* 2(4):271–280
52. Lin Y, Xing Z, She D et al. (2017) IDH mutant and 1p/19q co-deleted oligodendrogliomas: tumor grade stratification using diffusion-, susceptibility-, and perfusion-weighted MRI. *Neuroradiology* 59(6):555–62. <https://doi.org/10.1007/s00234-017-1839-6>
53. Yoon HJ, Ahn KJ, Lee S et al. (2017) Differential diagnosis of oligodendroglial and astrocytic tumors using imaging results: the added value of perfusion MR imaging. *Neuroradiology* 59(7):665–75. <https://doi.org/10.1007/s00234-017-1851-x>
54. Jenkinson MD, Smith TS, Joyce KA et al. (2006) Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. *Neuroradiology* 48(10):703–13.
55. Chawla S, Krejza J, Vossough A et al. (2013) Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast-perfusion-weighted imaging and proton MR spectroscopy. *AJNR Am J Neuroradiol* 34(8):1542–49. <https://doi.org/10.3174/ajnr.A3384>
56. Emblem KE, Scheie D, Due-Tønnessen P et al. (2008) Histogram analysis of MR imaging-derived cerebral blood volume maps: combined glioma grading and identification of low-grade oligodendroglial subtypes. *AJNR Am J Neuroradiol* 29(9):1664–70. <https://doi.org/10.3174/ajnr.A1182>
57. Emblem KE, Nedregård B, Nome T et al. (2008) Glioma grading by using histogram analysis of blood volume heterogeneity from MR-derived cerebral blood volume maps. *Radiology* 247(3):808–17. <https://doi.org/10.1148/radiol.2473070571>
58. Dietrich O, Reiser MF, Schoenberg SO (2008) Artifacts in 3T MRI: physical background and reduction strategies. *Eur J Radiol* 65(1):29–35
59. Vargas MI, Delavelle J, Kohler R, Becker CD, Lovblad K (2009) Brain and spine MRI artifacts at 3 Tesla. *J Neuroradiol* 36(2):74–81. <https://doi.org/10.1016/j.neurad.2008.08.001>
60. Kang Y, Choi SH, Kim YJ (2011) Gliomas: histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging—correlation with tumor grade. *Radiology* 261(3):882–90. <https://doi.org/10.1148/radiol.11110686>
61. Zhou M, Scott J, Chaudhury B et al. (2018) Radiomics in brain tumor: image assessment, quantitative feature descriptors, and machine-learning approaches. *AJNR Am J Neuroradiol* 39(2):208–16. <https://doi.org/10.3174/ajnr.A5391>
62. Zhang X, Yan LF, Hu YC et al. (2017) Optimizing a machine learning based glioma grading system using multi-parametric MRI histogram and texture features. *Oncotarget* 8(29):47816–830. <https://doi.org/10.18632/oncotarget.18001>
63. Lee MH, Kim J, Kim ST et al. (2019) Prediction of IDH1 mutation in GBM using machine learning technique based on quantitative radiomic data. *World Neurosurg* 125:e688–e696. <https://doi.org/10.1016/j.wneu.2019.01.157>